0
Veterans’ Prostate Cancer Treatment and Research Act
12/31/2022, 5:04 AM
Summary of Bill HR 4880
The bill aims to establish a program within the Department of Veterans Affairs (VA) that focuses on providing comprehensive and timely treatment for veterans diagnosed with prostate cancer. This program would include access to state-of-the-art treatment options, as well as support services for veterans and their families.
Additionally, the bill seeks to enhance research efforts related to prostate cancer within the VA. This includes increasing funding for research projects aimed at improving the understanding of prostate cancer, developing new treatment options, and ultimately finding a cure for the disease. Overall, the Veterans’ Prostate Cancer Treatment and Research Act is designed to address the unique healthcare needs of veterans diagnosed with prostate cancer. By providing better access to treatment and supporting research efforts, this bill aims to improve outcomes for veterans affected by this disease.
Congressional Summary of HR 4880
Veterans' Prostate Cancer Treatment and Research Act
This bill requires the Department of Veterans Affairs (VA) to establish in its National Surgery Office an interdisciplinary clinical pathway for all stages of prostate cancer. Clinical pathways are health care management tools designed around research and evidence-based practices that provide direction for the care and treatment of a specific condition. The clinical pathway must include specified elements, such as a diagnosis pathway and a treatment pathway.
The VA must consult with and incorporate feedback from (1) veterans who have received prostate cancer care at its medical facilities, and (2) experts in multidisciplinary cancer care and clinical research.
Additionally, the VA must publish the clinical pathway on a public VA website and annually update the pathway as needed based on medical literature and evidence-based guidelines.
The bill also requires the VA to submit a plan to establish a prostate cancer program using the comprehensive prostate cancer clinical pathway.





